Summary

• Page properties (1 modified, 0 added, 0 removed)

Details

Page properties

Content

...	...	@@ -62,59 +62,40 @@
62	62
63	63	== Therapies ==
64	64
65		-Forty years ago, Cipla started its fight against heart disease with innovative and high-class drugs. Over the years, Cipla has been developing several products that help treat various diseases like MI, angina, heart failure, hypertension, arrhythmia, lipid abnormalities and diabetes, and obesity.
	65	+Forty years ago, Cipla started its fight against heart disease with innovative and high-class drugs. Over the years, Cipla has been developing several products that help treat various diseases like MI, angina, heart failure, hypertension, arrhythmia, lipid abnormalities and diabetes, and obesity.{{footnote}}https://www.cipla.com/our-offerings/our-therapies{{/footnote}}
66	66
67		-[[https:~~/~~/www.cipla.com/our-offerings/our-therapies>>url:https://www.cipla.com/our-offerings/our-therapies]]
	67	+== API ==
68	68
69		-
70		-API
71		-
72		-
73	73	The company's mission of providing affordable medicines across many therapeutic areas globally is duly supported by the relentless efforts of its team of over 300 dedicated and talented scientists.
74	74
75		-To maintain the gold standard in its innovations, the company house state-of-the-art research facilities for its API process development at three locations in India, with dedicated teams working on synthetic, organic chemistry, process engineering and analytical development at multiple locations.
	71	+To maintain the gold standard in its innovations, the company house state-of-the-art research facilities for its API process development at three locations in India, with dedicated teams working on synthetic, organic chemistry, process engineering and analytical development at multiple locations.{{footnote}}https://www.cipla.com/our-offerings/api{{/footnote}}
76	76
77		-[[https:~~/~~/www.cipla.com/our-offerings/api>>url:https://www.cipla.com/our-offerings/api]]
78		-
79	79	The company's API pipeline consists of 75+ complex developments in the therapy areas of Oncology, Hep C, ARV, Diabetology, CVS, CNS, Respiratory etc.
80	80
	75	+= Manufacturing =
81	81
82		-Manufacturing
	77	+The company continuously work towards enhancing the affordability of medicines worldwide by investing in its manufacturing capital through facilities that are cGMP compliant and approved globally.{{footnote}}https://www.cipla.com/about-us/manufacturing{{/footnote}}
83	83
84		-The company continuously work towards enhancing the affordability of medicines worldwide by investing in its manufacturing capital through facilities that are cGMP compliant and approved globally.
85		-
86		-[[https:~~/~~/www.cipla.com/about-us/manufacturing>>url:https://www.cipla.com/about-us/manufacturing]]
87		-
88		-
89	89	Cipla has leveraged and invested in its manufacturing capital through facilities that are cGMP compliant and approved globally. This has facilitated the company to attain a global leadership position in the pharmaceutical sector.
90	90
91		-
92	92	Cipla has over 1500 products in 65 therapeutic categories available in over 50 dosage forms. These capabilities range from the development of a simple molecule to highly complex multi-chiral centres molecule with a distinction of affordability and highest quality. The company's capacities include its own facilities and in licensed facilities which support both generic and the biotech business. The company's investments in manufacturing capital include development of new drug delivery systems, facilitation of infrastructure supporting API and formulation developments and strengthening of platform technologies.
93	93
94		-
95	95	Cipla has scaled up several key APIs through yield improvement, cycle time reduction and cost improvement projects. The continued focus on process and operational improvements has resulted in reducing solvent losses to less than 15% thereby reducing environmental impact. Similarly, batch size increase of about 45 products in formulations was carried out during the year resulting in improvement in productivity. Cipla is now on a path to digitise the manufacturing operations by integrating all process-related machines to server to capture real-time process parameters for better operations control, improvement in productivity, and enhanced compliance status.
96	96
97		-
98	98	Cipla’s state-of-the-art manufacturing facilities are cGMP compliant in conformity with national and international standards. Several dosage forms and APIs manufactured at these facilities continue to be approved by major international regulatory agencies including the US FDA, MHRA (UK), TGA (Australia), Federal Ministry of Health-Germany, MCC (South Africa), the Department of Health (Canada), INVIMA (Columbia) ANVISA (Brazil), the Danish Medical Agency, WHO and Ministry of Health of various countries.
99	99
	87	+== API ==
100	100
101		-API
102		-
103	103	The company's API legacy spans over five decades of having serviced the world’s largest pharmaceutical companies.
104	104
105		-
106	106	With its 50+ years’ experience in manufacturing APIs, Cipla has produced 200+ generics and complex APIs. The company's API Business covers 60 countries across the globe. The Company continues to be a preferred partner to some of the largest generic formulators globally due to its focus on niche molecules and quality. A strong dedicated team of over 250+ scientist aids the Company to differentiate itself with the capability to handle wide range of chemistries and complex molecules. Cipla has a strong partnership with the world’s largest generic pharmaceutical companies.
107	107
108		-
109	109	The Company plans to enhance its API R&D and manufacturing capacities in therapeutic areas such as Respiratory and Oncology and conduct backward integration for manufacturing of Key Starting Material and critical API intermediates to have more control on the supply chain. Cipla is keen to partner with leading generic companies for their new products to further expand in markets such as Japan, China and the Commonwealth of Independent States (CIS) countries. Cipla has four sites with dedicated facilities for high potent APIs, corticosteroids, polypeptides, hormones, steroids and oncology with a total capacity of over 1,000 MT across.
110	110
	95	+== Formulation development ==
111	111
112		-Formulation development
113		-
114	114	Cipla is consistently developing a formulation portfolio and pipeline across its formulation facilities:
115	115
116		-.
117		-
118	118	Formulation development is focused on Respiratory, Oncology, ARVs, Ophthalmology, CNS, CVS among others Over 60% of the products are developed for international markets The pipeline has over 250 products, including complex formulations
119	119
120	120